Wang X, Yu X, Krauthammer M, et al. - Given that MUC16 is a mucin marker that is frequently mutated in melanoma, researchers desired to know whether MUC16 mutations could be useful as a surrogate biomarker for tumor mutation burden (TMB). This research rigorously assesses the MUC16 mutation as a clinical biomarker in cutaneous melanoma by using genomic and clinical data from patient samples from The Cancer Genome Atlas and two independent validation cohorts. The analysis was further extended to studies in patients treated with immunotherapies. Analysis outcomes exhibited that samples with MUC16 mutations had a higher TMB than the samples of wild-type, with strong statistical significance in all melanoma cohorts tested. MUC16 mutation seems a useful predictive marker for global TMB and melanoma patient survival.